The value of cysteinyldopa in the follow-up of disseminated malignant melanoma
| Autor: | Kerstin Årstrand, C Lindholm, Bertil Kågedal, B Nilsson, Ulrik Ringborg, R Kärnell |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Pathology Indoles Skin Neoplasms Dermatology Urine Gastroenterology chemistry.chemical_compound Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Biomarkers Tumor Humans Stage (cooking) Melanoma Aged Aged 80 and over business.industry Middle Aged medicine.disease Cysteinyldopa Oncology chemistry Disease Progression Female business Follow-Up Studies |
| Zdroj: | Melanoma research. 10(4) |
| ISSN: | 0960-8931 |
| Popis: | In a series of 92 patients with malignant melanoma, clinical stage III or IV, both 5-S-cysteinyldopa (5SCD) and 6-hydroxy-5-methoxyindole-2-carboxylic acid (6H5MI2C) were measured in urine during chemotherapy. A total of 434 urine specimens were analysed. The sensitivity of 5SCD for the detection of stage III-IV melanoma was 83%, while the corresponding sensitivity of 6H5MI2C was 52%. Fifty per cent of patients with one metastatic site had increased 5SCD excretion, while all patients with four or more metastatic sites had increased excretion. A significant correlation was found between 5SCD decrease and clinical regression (P0.001) and between 5SCD increase and clinical progression (P0.001). Corresponding correlations were not found for 6H5MI2C. Increments in 5SCD excretion (median 269 micromol/mol creatinine) were seen for 83% of the occasions when clinical progression was recorded, and decrements in 5SCD excretion (median 145 micromol/mol creatinine) were seen for 85% of the occasions when clinical regression was seen. During clinical 'stable disease' increases in 5SCD excretion were seen in 59% and decreases in 41%. The median value of 5SCD changes for stable disease was 7.0 micromol/mol creatinine, indicating a chemical marker stability in many cases. We recommend the use of 5SCD in urine as a valuable, reliable and simple biochemical marker to use in the clinical follow-up of melanoma patients with advanced disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|